Gilead raises sales outlook to include Covid-19 treatment remdesivir


By Deena Beasley and Michael Erman (Reuters) - Gilead Sciences Inc on Thursday posted worse-than-expected quarterly results, but raised its 2020 sales forecast to include revenue from its antiviral drug remdesivir, one of the only treatments shown to help COVID-19 patients. Gilead said it expects total 2020 sales of $23 billion to $25 billion, up from its previous range of $21.8 billion to $22.2 billion.

"We think this implies up to $1 billion to $3 billion of remdesivir, ... a positive that was not expected at the start.

This article is no longer available in our repository.

There could be multiple reasons for this.